| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2971545 | The Journal of Heart and Lung Transplantation | 2011 | 6 Pages |
Abstract
The CYP3A5*1 genetic polymorphism is a promising marker to identify heart transplant recipients least likely to develop renal dysfunction during long-term treatment with a calcineurin inhibitor.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Simon BPharm, MSc, PhD, Marcin BPharm, MSc, Amina PhD, Marie-Hélène MD, Normand MD, François MSc, Michel MD, Anique MD, MSc, Marie-Pierre PhD, Jacques BPharm, PhD, Michel MD,